Fig. 6

In vivo investigation for the intratumoral accumulation of ApoLNP with different administration routes (a) 4T1 tumor-bearing mice were administered with ApoLNPs (0.15 or 3 mg/kg, based on DOX content) via IV, IT, and MSC-guided routes and their IVIS images were collected for 48 h (fluorescence signals of Flamma 648-PE in 10PS). b The in vivo tumor fluorescent intensities were calculated and described as a function of time. c After 48 h of intravenous, intratumoral, and MSC-guided ApoLNP treatment, tumor tissues were extracted to take their ex vivo IVIS images, and (d) their fluorescent intensities were measured (n = 3). e The distribution of ApoLNPs inside IV, IT, and MSC-guided administered tumors was assessed using the CLSM. f The pharmacokinetics of ApoLNPs administered via different routes were analyzed by quantifying the changes in blood plasma concentrations of ApoLNPs over 48 h through the HPLC. ns = not significant, *** p < 0.001, **** p < 0.0001